Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zihuol Tablets is an investigational traditional Chinese medicine (TCM), specifically a Tibetan medicine-derived natural product, developed by Qinghai Yangzong Pharmaceutical for the treatment of type 2 diabetes mellitus. The drug is formulated as an oral tablet and has been evaluated in Phase 1 clinical trials in China (e.g., CTR20191273) to assess its safety, tolerability, and pharmacokinetics in healthy adults, as well as its exploratory glucose-lowering effects. As a botanical-based therapy, Zihuol Tablets likely exerts its effects through multi-target regulation of metabolic pathways associated with glucose homeostasis, consistent with the holistic approach of traditional herbal formulations used in metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zihuol Tablets.